Cable Hill Partners’s Amicus Therapeutics FOLD Stock Holding History

Cable Hill Partners’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-168	Closed	-$2K	–	328
2019 Q1	$2K	Hold	168	–	–	﹤0.01%	748
2018 Q4	$2K	Hold	168	–	–	﹤0.01%	706
2018 Q3	$2K	Sell	168 -530	-76%	-$7.41K	﹤0.01%	712
2018 Q2	$11K	Sell	698 -250	-26%	-$3.78K	﹤0.01%	451
2018 Q1	$12K	Buy	948 +421	+80%	+$6.41K	0.01%	436
2017 Q4	$8K	Hold	527	–	–	﹤0.01%	619
2017 Q3	$8K	Sell	527 -473	-47%	-$6.26K	﹤0.01%	635
2017 Q2	$10K	Buy	+1,000	New	+$8.05K	0.01%	407

Other funds holding FOLD

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Cable Hill Partners's FOLD Position: Q2 2019 in Review

Cable Hill Partners sold out of Amicus Therapeutics (FOLD) in Q2 2019, closing a stake of 168 shares — an estimated $2K sold.

Cable Hill Partners first reported a position in FOLD in Q2 2017 and held it in 8 quarters. The position peaked at $12K in Q1 2018. 206 funds tracked by Wall St. Rank hold FOLD as of Q2 2019.

Cable Hill Partners reported no remaining Amicus Therapeutics position as of Q2 2019 after selling out during the quarter.
Cable Hill Partners sold 168 Amicus Therapeutics shares in Q2 2019, an estimated $2K.
Cable Hill Partners first reported a position in Amicus Therapeutics in Q2 2017 and held it in 8 quarters.
Cable Hill Partners's Amicus Therapeutics position peaked at $12K in Q1 2018.
206 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2019.

Based on Cable Hill Partners's 13F filing for Q2 2019, filed 6 Aug 2019.